Blossomhill Therapeutics
Clinical trials sponsored by Blossomhill Therapeutics, explained in plain language.
-
First patients to try new pill for Tough-to-Treat leukemia
Disease control Recruiting nowThis is the first time researchers are giving a new oral drug called BH-30236 to people. The study aims to find a safe dose and see if the drug can help control two aggressive blood cancers—acute myeloid leukemia or myelodysplastic syndrome—that have come back or haven't responde…
Phase: PHASE1 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New pill targets Tough-to-Treat lung cancer mutations
Disease control Recruiting nowThis early-stage study is testing a new oral drug called BH-30643 in adults with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR or HER2 mutations). The first part aims to find a safe and effective dose. The second part will see how well the dr…
Phase: PHASE1, PHASE2 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC